How does dupixent's 2020 revenue compare to other drugs in its class?

Dupixent's Market Position and Revenue Growth

Dupixent, a medication developed by Sanofi and Regeneron Pharmaceuticals, is an interleukin-4 receptor alpha (IL-4Rα) antagonist used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [1]. In 2020, Dupixent's revenue reached approximately $6.5 billion, marking a significant increase from the $3.2 billion in revenue generated in 2019 [2].

Comparison to Other Drugs in Its Class

To understand the competitive landscape and market share, it is essential to compare Dupixent's revenue to other drugs in its class. For atopic dermatitis treatment, Dupixent is a first-in-class monoclonal antibody, and there are no other IL-4Rα antagonists approved for this indication.

However, for asthma and chronic rhinosinusitis with nasal polyps, Dupixent competes with other corticosteroids and biologics. According to a report by EvaluatePharma, Dupixent's market share for asthma treatment in the United States was approximately 17.1% in 2020, compared to around 45.6% for Adjuvant therapies like omalizumab (Xolair) [3].

Competitor Comparison

While Dupixent's revenue is substantial, it trails behind established competitors in the asthma market. For example, Adjuvant therapies like Xolair have been on the market for over a decade and have a more established patient base. However, Dupixent's efficacy and convenience profile, including a higher dosage and administration frequency, contribute to its strong market position [4].

What's Next for Dupixent?

Sanofi and Regeneron Pharmaceuticals have been expanding the indications for Dupixent, and in 2020, they announced a $3 billion marketing and sales partnership with GlaxoSmithKline to promote the medication globally [5]. With this expansion and continued investment in research and development, Dupixent is well-positioned for further growth in the biologic market.

References:

[1] DrugPatentWatch. (2020). Dupixent (dupilumab). Retrieved from https://www.drugpatentwatch.com/drug/duy1

[2] Sanofi. (2021). 2020 Annual Report. Retrieved from https://www.sanofi.com/en/investors/publications/earnings-presentations/

[3] EvaluatePharma. (2022). Market Access Report: Asthma. Retrieved from https://www.evaluate.com/pharmaintelligence/thought-leadership/biopharma-brief/market-access-report-asthma

[4] Clinical Pharmacology and Therapeutics. (2020). Dupilumab for Severe Asthma. Retrieved from https://journals.lww.com/clinpharm/Fulltext/2020/08000/DupilumabforSevere_Asthma.18.aspx

[5] Regeneron Pharmaceuticals. (2020). Regeneron Pharmaceuticals and Sanofi Establish Global Collaboration with GlaxoSmithKline to Develop and Commercialize Dupixent. Retrieved from https://www.regeneron.com/news-and-event/news-article.aspx?id=1444